The BioMonitor IV features AI capabilities for false positive reduction. The AI cuts false positives for AFib, bradycardia, tachycardia and pause. According to Biotronik, its SmartECG reduces 86% of false detections across all major arrhythmias while keeping 98% of the clinically relevant episodes.
It also offers premature ventricular and atrial contraction (PVC and PAC) discrimination capabilities. Biotronik said in a news release that this makes it the first and only ICM on the market with those capabilities. BioMonitor IV also features strong signal quality and transmission success for highly reliable remote patient management.
Biotronik said its system offers significant workflow enhancements through automaticity and intuitive templates and reports. The company based all the improvements on advanced algorithms with a fully explainable machine learning system for false AFib filtering.
The company presented its new ICM at the EHRA Congress in Berlin this week.
“AI and connected cardiac solutions have the potential to revolutionize healthcare,” said Biotroink President of CRM/EP Dr. Andreas Hecker. “Our latest innovation, BioMonitor IV, will propel the field of cardiac monitoring in this new direction. Biotronik was the first company to introduce remote care of cardiac rhythm devices over 20 years ago. Today, we will lead a new direction in intelligent systems that streamlines clinicians’ workflow and turns an industry overwhelmed with data into personalized and actionable care.”
